Starton Therapeutics Inc CEO Pedro Lichtinger talks to Proactive about achievements the Paramus, New Jersey-based company made in 2021.
Lichtinger also talked through the significance of receiving its first Clinical Trial Authorization in the Netherlands to start a Phase 1 study on its STAR-LLD continuous delivery lenalidomide.